Table 3.

Ongoing clinical trials for chondrosarcoma. Twenty-three (2 with radiation therapy; 21 with novels) clinical trials for chondrosarcoma were found using the following keywords: chondrosarcoma, bone sarcomas, solid tumors (https://clinicaltrials.gov and https://www.clinicaltrialsregister.eu/, accessed on 3 April 2021).

Clinical Trial	Agent/ Interventions	Phase	Study Population	Status
NCT04278781	AG-120	Phase 2	IDH1 mutant chondrosarcoma	Recruiting
NCT02389244	Regorafenib	Phase 2	Metastatic bone sarcoma, chondrosarcoma	Recruiting
NCT04040205	Abemaciclib	Phase 2	Advanced bone sarcoma, including chondrosarcoma	Recruiting
NCT03173976	Zoledronic acid	Phase 1b	Resectable chondrosarcoma	Recruiting
NCT04340843	Combination belinostat and guadecitabine	Phase 2	Conventional Chondrosarcoma	Not yet recruiting
NCT03277924	Nivolumab plus Sunitinib	Phase 1/2	Advanced bone sarcomas	Recruiting
NCT03190174	Combination nivolumab and nab-rapamycin (ABI-009)	Phase 1/2	Advanced malignancies, including sarcomas with deficient mismatch repair	Active, not recruiting
NCT03474640	Toripalimab	Phase 1	Advanced malignancies including chondrosarcoma	Recruiting
NCT04690725	TQB3525	Phase 1 Phase 2	Advanced Bone Sarcomas	Active, not recruiting
NCT04762602	HMPL-306	Phase 1	Isocitrate Dehydrogenase Gene Mutation	Not recruiting
NCT03670069	Itacitinib	Phase 1	Metastatic Chondrosarcoma Sarcoma Tumor Immune Microenvironment	Recruiting
NCT03449108	Aldesleukin Autologous Tumor-Infiltrating Lymphocytes LN-145 Autologous Tumor-Infiltrating Lymphocytes LN-145-S1 Cyclophosphamide Fludarabine	Phase 2	Bone Sarcoma Dedifferentiated Chondrosarcoma Giant Cell Tumor of Bone Malignancy in Giant Cell Tumor of Bone Malignant Solid Neoplasm	Recruiting
NCT03684811	Drug: FT-2102 Drug: Azacitidine Biological: Nivolumab Drug: Gemcitabine and Cisplatin	Phase 1 Phase 2	Cohort 1a and 1b: Glioma Cohort 1a and 1b: Glioblastoma Multiforme Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas) Cohort 3a and 3b: Chondrosarcoma Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma Cohort 5a: Other Solid Tumors With IDH1 Mutations	Recruiting
NCT04521686	LY3410738	Phase 1	Cholangiocarcinoma Chondrosarcoma Any Solid Tumor	Recruiting
NCT04305548	Trabectedin	Phase 2	Advanced Rearranged Mesenchymal Chondrosarcoma	Not yet recruiting
NCT04458922	Atezolizumab	Phase 2	Chondrosarcoma NCI Grade 2 Chondrosarcoma NCI Grade 3 Clear Cell Sarcoma of Soft Tissue Dedifferentiated Chondrosarcoma Primary Central Chondrosarcoma	Recruiting
NCT01267955	Vismodegib	Phase 2	Clear Cell Chondrosarcoma Dedifferentiated Chondrosarcoma Locally Advanced Chondrosarcoma Mesenchymal Chondrosarcoma Metastatic Chondrosarcoma Primary Central Chondrosarcoma Unresectable Primary Central Chondrosarcoma	Active, not recruiting
NCT02821507	sirolimus and cyclophosphamide	Phase 2	Conventional Chondrosarcoma Myxoid Liposarcoma Mesenchymal Chondrosarcoma Dedifferentiated Chondrosarcoma	Recruiting
NCT02066285	Pazopanib	Phase 2	Solitary Fibrous Tumor Extraskeletal Myxoid Chondrosarcoma	Active, not recruiting
2010-019817-20	GDC-0449	Phase 2	Advanced chondrosarcomas	Ongoing
NCT04260113	Apatinib Mesylate	Not Applicable	Unresectable Advanced Chondrosarcoma	Active, not recruiting
NCT02073994	AG-120	Phase 1	Cholangiocarcinoma Chondrosarcoma Glioma Other Advanced Solid Tumors	Active, not recruiting
NCT02048371	Regorafenib	Phase 2	Liposarcoma Osteogenic Sarcoma Ewing’s/Ewing-like Sarcoma Rhabdomyosarcoma Mesenchymal Chondrosarcoma	Recruiting
NCT01182753	Radiation: carbon ion therapy Radiation: proton therapy	Phase 3	Chondrosarcoma	Recruiting
NCT02838602	Radiation: Carbon ions therapy Radiation: Advanced external radiotherapy by Xrays or protons	Not Applicable	Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma, and Sarcoma	Recruiting